Castle Biosciences expects to meet or exceed guided FY22 revenue of $132M-$137M

Castle Biosciences said it expects to meet or exceed the top end of its previously guided range of $132M-$137M million for full-year 2022 total revenue. Consensus at $133.5M. The company delivered 12,563 total test reports in the fourth quarter of 2022, compared to 8,242 in the same period of 2021, an increase of 52%. Total test reports delivered in 2022 were 44,338, compared to 28,118 in the same period of 2021, an increase of 58%. Year-end 2022 cash and cash equivalents are expected to be approximately $123M. Additionally, the company expects to hold approximately $136M in short-term investments.